Skip to main content

Multifunctional perfluorooctylbromide alginate microcapsules for monitoring of mesenchymal stem cell delivery using CT and MRI

Background and objectives

Many patients with peripheral arterial disease (PAD) cannot undergo conventional medical or surgical therapy due to the extent or severity of atherosclerotic disease. Stem cell therapy has shown promising results as an angiogenic therapy in PAD patients. However, the poor survival of transplanted cells due to early immunodestruction and the inability to noninvasively monitor and track the distribution and proliferation of transplanted cells hinders stem cell therapeutic efficacy. We present here a multifunctional mesenchymal stem cell (MSC) microencapsulation and trafficking method utilizing perfluorooctylbromide (PFOB) incorporated alginate-poly-L-lysine-alginate microcapsules (PFOB Caps) for MSC delivery and noninvasive engraftment tracking using clinical X-ray and MR imaging equipment.

Methods

Microencapsulation of bone marrow-derived rabbit or human MSCs (1.5 × 106cells/ml) were performed by extruding a PFOB-impregnated 2% (w/v) alginate solution from a syringe pump in conjunction with an electrostatic droplet generator, followed by cross linking with poly-L-lysine to form X-ray- and MRI-visible microcapsules. MSCs viability was examined and compared between unlabeled capsules and PFOB Caps. Using 19F MRI and rotational angiograms reconstructed into CT-like images, the minimum detectable concentration was determined in phantoms using standard clinical imaging systems. X-ray delivery and tracking of intramuscular injections of PFOB Caps (~5000 capsules/injection) was assessed in a rabbit PAD model.

Results

The viability of rabbit MSCs encapsulated with PFOB was 90 ± 3% immediately after encapsulation and remained high (88 ± 5% at 4 weeks post-encapsulation). PFOB Caps containing human MSCs had enhanced cell viability relative to unlabeled capsules (83 ± 3% for PFOB vs. 50 ± 1% for control at 65 days post-encapsulation, P < 0.001). Viability of human MSCs in PFOB Caps was maintained up to 100 days, while it decreased sharply to <10% in unlabeled capsules at 80 days post-encapsulation. In vitro CT and 19F MRI imaging of PFOB Caps demonstrated the ability to detect as few as 2 and 25 capsules (Figure 1), respectively. In vivo, PFOB visibility on CT images was demonstrated relative to unlabeled capsules with persistence of intact microcapsules up to 5 weeks post delivery in PAD rabbits.

Figure 1
figure1

In vito DynaCT and 19F MR images of PFOB Caps phantoms. (A, B) DynaCT images of PFOM Caps phantoms demonstrated the ability to detect as few as 2 capsules. (C) 19F MRI (3D-TrueFISP, BW = 1500 Hz/px, TR/TE = 3.0/1.5 ms, 2.0 × 2.0 × 5.0 mm3, 24 partitions, 4 avgs, 62 s acquisition) of the same phantom as B showed as few as 25 PFOB Caps were identifiable.

Conclusion

By adding PFOB, a dual contrast agent and oxygen carrier, to alginate microcapsules, we have demonstrated the enhanced viability of MSCs within PFOB Caps, and the ability to deliver and track engraftment of stem cells using multiple conventional clinical imaging systems in vivo.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Yingli Fu.

Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Fu, Y., Kedziorek, D., Ouwerkerk, R. et al. Multifunctional perfluorooctylbromide alginate microcapsules for monitoring of mesenchymal stem cell delivery using CT and MRI. J Cardiovasc Magn Reson 11, O7 (2009). https://doi.org/10.1186/1532-429X-11-S1-O7

Download citation

Keywords

  • Mesenchymal Stem Cell
  • Peripheral Arterial Disease
  • Human MSCs
  • Stem Cell Delivery
  • Peripheral Arterial Disease Patient